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Abstract
Background: Human infections with highly pathogenic H5N1 avian influenza viruses have generally been confirmed by
molecular amplification or culture-based methods. Serologic surveillance has potential advantages which have not been
realized because rapid and specific serologic tests to detect H5N1 infection are not widely available.
Methodology/Principal Findings: Here we describe an epitope-blocking ELISA to detect specific antibodies to H5N1 viruses
in human or animal sera. The assay relies on a novel monoclonal antibody (5F8) that binds to an epitope comprising amino
acid residues 274–281 (CNTKCQTP) in the HA1 region of H5 hemagglutinin. Database search analysis of publicly available
sequences revealed that this epitope is conserved in 100% of the 163 H5N1 viruses isolated from humans. The sensitivity
and specificity of the epitope-blocking ELISA for H5N1 were evaluated using chicken antisera to multiple virus clades and
other influenza subtypes as well as serum samples from individuals naturally infected with H5N1 or seasonal influenza
viruses. The epitope-blocking ELISA results were compared to those of hemagglutinin inhibition (HI) and microneutraliza-
tion assays. Antibodies to H5N1 were readily detected in immunized animals or convalescent human sera by the epitope-
blocking ELISA whereas specimens with antibodies to other influenza subtypes yielded negative results. The assay showed
higher sensitivity and specificity as compared to HI and microneutralization.
Conclusions/Significance: The epitope-blocking ELISA based on a unique 5F8 mAb provided highly sensitive and 100%
specific detection of antibodies to H5N1 influenza viruses in human sera.
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Introduction
Highly pathogenic avian influenza (HPAI) H5N1 was first
detected among poultry in China in 1996. One year later, H5N1
virus emerged in Hong Kong to cause fatal respiratory infections
in humans [1]. Since then, HPAI H5N1 virus has continued to
spread, causing outbreaks in birds and mammals in over fifty
countries of the Old World [2]. Zoonotic H5N1 influenza
transmission resulted in 387 confirmed human infections and
245 fatalities (as of August 2008) [3]. Indonesia has reported a high
case fatality rate; 112 deaths among 137 cases of infection [3,4].
Based upon the available epidemiologic surveillance data, the
world is now in phase 3 (of 6) of a pandemic alert, according to the
World Health Organization (WHO) [5,6].
Serological investigations to detect specific antibodies from
H5N1 infection or vaccination in humans and poultry are critical
to the success of disease prevention and control programs. Several
serologic tests are available, including hemagglutination inhibition
(HI), microneutralization, enzyme linked immunosorbent assay
(ELISA) and agar gel precipitation. However, HI tests have limited
value for detecting antibodies against H5N1 viruses in humans
and other mammals because of their low sensitivity, subtype cross-
reactivity, and inter-assay variability [7,8]. The microneutraliza-
tion assay is currently recommended for detection of antibodies to
HPAI H5N1 [9]. However, this test is labor-intensive and requires
access to biocontainment facilities [10], rendering it impractical for
rapid and high-throughput diagnostics [11]. The H5N1 ELISA
(indirect ELISA) has been widely used in serologic surveillance of
chicken and turkey flocks. However, cross-reacting antibodies
elicited by infection or vaccination with seasonal influenza virus
can yield false positive H5N1 test results that reduce the value of
indirect H5N1 ELISA in humans [11].
We developed epitope-blocking ELISA (EB-ELISA) to detect
serum antibodies to H5N1 viruses with high sensitivity and
specificity. This assay yields a positive result when antibodies to the
H5 hemagglutinin (HA) in test sera block binding of a labeled
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4566monoclonal antibody (mAb) to the H5 antigen. In practice, the
intensity of the colored reaction product resulting from antigen-
bound mAb is inversely proportional to the amount of epitope-
specific antibody present in test serum [12,13]. The biological
significance of the test is determined by the epitope specificity of
the mAb used in the EB-ELISA, and its broad applicability
depends on the conservation of the epitope among H5N1 viruses.
Further, the epitope recognized by the mAb should be highly
antigenic so that antibodies to this epitope are consistently elicited
in infected or vaccinated hosts. Here, we describe an EB-ELISA
based on a mAb that meets these requirements. We evaluate the
sensitivity and specificity of this method using experimental
chicken anti-sera and demonstrate its advantages with H5N1
convalescent human sera.
Materials and Methods
Viruses
Human (n=24) and avian (n=2) influenza A viruses (subtype
H5N1, clade 2.1) isolated in Indonesia were obtained from the
Ministry of Health (MOH), Republic of Indonesia (Table 1).
Influenza A viruses from other subtypes were obtained from the
Agri-Food and Veterinary Authority (AVA) of Singapore (Table 1).
A reassortant H5N1 virus containing the HA and NA from A/
Vietnam/1203/04 (H5N1) in A/Puerto Rico/8/1934 (PR8)
genetic background was described previously (14). High and low
pathogenic viruses were propagated in the allantoic cavity of 11
day-old embryonated chicken eggs [15]. Virus titers were
determined using a standard hemagglutination assay [16]. All
viruses were clarified by centrifugation at 20,0006g for 20 min at
4uC, inactivated with formaldehyde as described previously [17]
and stored at 280uC. Inactivated A/Indonesia/CDC669/2006
H5N1 virus was further concentrated by ultracentrifugation at
100,0006g for 2 h. All experiments with live viruses were
performed in a biosafety level 3 (BSL-3) containment laboratory
in compliance with CDC/NIH and WHO recommendations
[18,19] and approved by the Agri-Food and Veterinary Authority
and Ministry of Health of Singapore.
Reverse genetics
The HA and NA genes of 17 viruses of H5N1 subtype from
clades 1, 2, 4, 7 and 8 (Table 2) as well as subtypes H2N9, H6N8,
H8N4, H12N5 (Table 2) were synthesized (GenScript, USA) based
on sequences from the NCBI Influenza Database. The synthetic
HA and NA genes were cloned into a dual-promoter plasmid for
influenza A reverse genetics [14]. Reassortant viruses were rescued
by transfecting plasmids containing HA and NA along with the
remaining six influenza genes derived from A/Puerto Rico/8/34
into co-cultured 293T and MDCK cells using Lipofectamine 2000
(Invitrogen Corp). At 72 h post-transfection the culture medium
was inoculated into embryonated eggs or MDCK cells. The HA
and NA genes of reassortant viruses from the second passage were
sequenced to confirm presence of introduced HA and NA genes
and the absence of mutations.
Production of recombinant H5N1 HA0 protein (rHA0)
Viral RNA was extracted from allantoic fluid containing A/
Indonesia/CDC669/06 (H5N1) using a commercial guanidium-
phenol solution (Trizol Invitrogen, USA). The HA gene was
amplified from reverse-transcribed RNA and cloned into pQE-30
vector (Qiagen, Germany) followed by transformation into
Escherichia coli M15 pREP4 competent cells for protein expression
(sequences of primers used for HA amplification are provided in
supplementary file, Table S1 of the journal). Hexa-histidine-
tagged fusion HA expression was induced by the addition of
1 mmol/L IPTG for 3 h and purified on a Ni-NTA column
(Qiagen, Germany) [15].
Production and characterization of mAbs
BALB/c mice were immunized twice 2 weeks apart by
subcutaneous injection with 25 mg of rH5HA0 antigen mixed
with adjuvant (SEPPIC, France). Mice received an additional
intravenous injection of 25 mg of rH5HA0 antigen 3 days before
the fusion of splenocytes with SP2/0 cells [20]. The fused cells
were seeded in 96-well plates with selective medium, and their
supernatants were screened by immunofluorescence assays as
described below. Immunoglobulins from selected mAbs were
isotyped using a commercial kit (Amersham Bioscience, England).
Table 1. Avian influenza viruses used in this study.
Virus name
A/Indonesia/CDC7/06
a
A/Indonesia/CDC326/06
a
A/Indonesia/CDC329/06
a
A/Indonesia/CDC370/06
a
A/Indonesia/CDC390/06
a
A/Indonesia/CDC523/06
a
A/Indonesia/CDC594/06
a
A/Indonesia/CDC595/06
a
A/Indonesia/CDC597/06
a
A/Indonesia/CDC610/06
a
A/Indonesia/CDC623/06
a
A/Indonesia/CDC644/06
a
A/Indonesia/CDC669/06
a
A/Indonesia/TLL01/06
a
A/Indonesia/TLL02/06
a
A/Indonesia/TLL60/06
a
A/Indonesia/TLL177/06
a
A/Indonesia/TLL298/06
a
A/Indonesia/TLL485/06
a
A/Indonesia/TLL530/06
a
A/Indonesia/TLL535/06
a
A/Indonesia/TLL540/06
a
A/Indonesia/TLL561/06
a
A/Indonesia/TLL565/06
a
A/chicken/Indonesia/TLL101/06
a
A/duck/Indonesia/TLL102/06
a
A/chicken/Singapore/Sin/02
b
A/chicken/Singapore/Sin/92
c
A/common iora/Indonesia/F89/11/95
d
A/chicken/Singapore/Sin/98
e
A/mandarin duck/Singapore/Sin/93
f
The subtype of the virus used is indicated in superscript.
aH5N1.
bH3N2.
cH4N1.
dH7N1.
eH9N2.
fH10N5.
doi:10.1371/journal.pone.0004566.t001
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peroxidase (HRP) and purified from unbound enzyme using a
commercial kit (Pierce EZ-Link plus Activated Peroxidase Kit).
Immunofluorescence assay (IFA)
A recombinant baculovirus harboring the HA1-encoding region
(amino acids 1–325) from the A/Indonesia/CDC669/06 HA gene
was generated as described previously [21] for screening HA1-
specific mAbs by IFA. Sf-9 and MDCK cells cultured in 96-well
plates were infected with H5-HA1 recombinant baculovirus or
with a panel of influenza viruses including Indonesian H5N1
strains and other non-H5 subtype viruses (Table 1). The cells were
rinsed and fixed with 4% paraformaldehyde at 36 h (for Sf-9 cells)
and 24–48 h (for MDCK cells) post-infection. Fixed cells were
incubated with hybridoma supernatants at 37uC for 1 h, rinsed
with phosphate buffered saline (PBS) and then incubated with a
1:40 dilution of fluorescein isothiocyanate (FITC)-conjugated
rabbit anti-mouse immunoglobulin (Dako, Denmark). Antibody
binding was evaluated by wide-field epi-fluorescence microscopy
(Olympus IX71) [22].
Western blot
rH5HA0 expressing E. coli cultures were induced with IPTG,
and cell pellets were lysed in sample buffer and separated on 12%
SDS-PAGE. Proteins were then transferred onto nitrocellulose
membrane and blocked with 5% non-fat milk in PBST (16PBS
and 0.1% Tween-20) for 1 h at room temperature. The
membrane was incubated with hybridoma supernatant, rinsed
with PBST and incubated with horseradish peroxidase (HRP)-
conjugated rabbit anti-mouse IgG (Dako, Denmark) for 1 h at
room temperature. Following washing with PBST, the membrane
was developed using a chemiluminescent substrate (ECL Amer-
sham Biosciences) as described previously [23].
Epitope mapping of 5F8 mAb
Five partially overlapping fragments spanning the HA1-
encoding region of the H5 HA gene of A/Indonesia/CDC669/
06 were amplified by PCR and cloned into pQE-30 expression
vector (sequences of primers used for fragment amplification are
provided in the supplementary file, Table S2 of the journal). The
fusion-peptides were expressed in E. coli as described above and
analyzed by Western blot with anti-His antibody [23]. Eight
additional truncated peptides (sub-fragment SF1–SF8, spanning
amino acids 165–321; numbering for mature HA excluding signal
peptide) were expressed as histidine-fusion peptides as described
above and were used for Western blot analysis (sequences of
primers used for fragment amplification are provided in
supplementary file, Table S3 of the journal). A panel of fourteen
mutants of sub-fragment SF4 with single mutations at amino acid
residues 271–284 was produced by substituting each amino acid to
alanine, except alanine-281, which was mutated to glycine. The
point mutants were generated using the QuikChange Site-
Directed Mutagenesis kit’ (Stratagene, USA) following manufac-
turer’s instructions (sequences of primers used for each amino acid
substitution are provided in the supplementary file, Table S4 of the
journal). These mutants were also expressed as His-fusion peptides
in E. coli as described above.
5F8 epitope conservation analysis
In order to investigate the distribution of the 5F8 epitope among
the 16 known HA subtypes, we compared 4143 full-length influenza
AH As e q u e n c e sf r o ma v i a na n dh u m a ns o u r c e sa v a i l a b l ei nt h e
NCBI Influenza Database (http://www.ncbi.nlm.nih.gov/genomes/
FLU/Database/multiple.cgi) on August 26, 2008. The search was
limited to ‘‘full-length sequences only’’ and identical sequences were
removed. Alignment was performed using MUSCLE software to
identify sequences with mutations within the 5F8 epitope.
Experimental serum samples
Groups of White Leghorn chickens (n=5), three weeks of age,
were injected intramuscularly with each of 26 different inactivated
H5N1 virus isolates from Indonesia (Table 1) or inactivated
subtypes H3N2, H4N1, H7N1, H9N2 and H10N5 viruses
emulsified in ISA-70 (SEPPIC, France) adjuvant. The injections
were repeated twice at two-week intervals. In addition, 21 groups
of chickens were immunized as indicated above with seventeen
reassortant H5N1 viruses from clades 1, 2, 4, 7 and 8 (Table 2,
No. 1-17) and four strains representative of subtypes H2N9,
H6N8, H8N4 and H12N5 (Table 2, No. 18-21). Blood was
collected 10 days after the 1
st immunization and 10 days after the
2
nd immunization. Sera were evaluated for antibodies against
appropriate homologous strains by HI as described below.
Human serum panels
Panels of human sera (n=45) were divided into 3 groups.
Group 1 comprised 10 human sera collected three to six months
after infection with influenza H5N1, available from a serum
repository of the MOH of Indonesia. Group 2 consisted of 15
serum samples from patients recovered from seasonal influenza A
virus infections, available from the Repository of Singapore
General Hospital (SGH), Singapore. Group 3 consisted of 20
serum samples from healthy volunteers with a history of no clinical
Table 2. Reassortant influenza A viruses generated by reverse
genetics.
Serial No. Virus name (subtype)
# Clade Host
1 A/HongKong/213/03
* (H5N1) 1 Human
2 A/Vietnam/1203/04
* (H5N1) 1 Human
3 A/muscovy duck/Vietnam/33/07 (H5N1) 1 Avian
4 A/Indonesia/CDC1031/07 (H5N1) 2.1 Human
5 A/turkey/Turkey1/05
*(H5N1) 2.2 Avian
6 A/barheaded goose/Qinghai/12/05(H5N1) 2.2 Avian
7 A/Nigeria/6e/07(H5N1) 2.2 Human
8 A/muscovy duck/RostovonDon/51/07(H5N1) 2.2 Human
9 A/Egypt/0636-NAMRU3/07(H5N1) 2.2 Human
10 A/Anhui/1/05
*(H5N1) 2.3 Human
11 A/Jiangsu/2/07 (H5N1) 2.3 Human
12 A/chicken/Nongkhai/NIAH400802/07 (H5N1) 2.3 Avian
13 A/VietNam/HN31242/07 (H5N1) 2.3 Human
14 A/Hongkong/156/97 (H5N1) 0 Human
15 A/chicken/Shanxi/2/06 (H5N1) 7 Avian
16 A/goose/Guiyang/337/06 (H5N1) 4 Avian
17 A/chicken/Henan/12/04 (H5N1) 8 Avian
18 A/duck/Nanchang/4-184/2000 (H2N9) - Avian
19 A/shorebird/DE/12/04 (H6N8) - Avian
20 A/duck/Yangzhou/02/05 (H8N4) - Avian
21 A/pintail/Alberta/49/03 (H12N5) - Avian
#Donor of HA and NA genes for derivation of PR8 reassortant viruses.
*Candidate vaccine strains for H5N1 virus vaccine development.
doi:10.1371/journal.pone.0004566.t002
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from repositories of the MOH, Indonesia. The influenza exposure
status of patients was documented in medical records of the MOH
of Indonesia; individual identifiers were anonymized in compli-
ance with applicable human subjects protection regulations.
Epitope-Blocking ELISA
Optimal dilutions of purified H5N1 viral antigen or recombi-
nant HA0 and mAb were determined by checkerboard titration to
yield sub-saturating levels of the mAb. U-bottomed 96-well ELISA
plates were coated with purified recombinant HA of A/Indonesia/
CDC/669/06 prepared as described above (500 ng/well) or
inactivated concentrated H5N1 virus (10 mg/well) and incubated
overnight at 4uC in coating buffer (0.1 mol/L carbonate/
bicarbonate, pH 9.6). Antigen-coated plates were washed with
PBS (pH 7.5) containing 0.05% Tween 20 (PBST) and non-
specific sites were blocked with 100 mL blocking buffer (PBS
containing 5% skim milk) for 40 min at 37uC. Test serum samples
were serially diluted two fold in PBST, and 100 mL was added to
each well and incubated for 45 min at 37uC. The wells were rinsed
four times with PBST and incubated with ,120 ng of HRP-
conjugated anti-H5 mAb 5F8 in 100 mL PBST for 1 h at 37uC.
The wells were rinsed with PBST and incubated with 100 mLo f3 ,
39,5 ,5 9-tetramethyl benzidine (TMB, Sigma, USA). The reaction
was stopped by adding 0.1N Sulfuric acid and the optical density
(OD) determined at 450 nm using a multiwell plate reader.
The OD intensity reduction caused by serum antibodies
blocking mAb binding was calculated for each sample dilution
by using the formula: % inhibition=[(negative reference serum
OD2test serum OD)/(negative reference serum OD2positive
reference serum OD)]6100%. To determine the cut-off value, 126
specific pathogen-free chicken sera were obtained from the Animal
Health Biotechnology Serum Bank, Temasek Life Sciences
Laboratory, Singapore.
Hemagglutination inhibition assay
Hemagglutination inhibition assays were performed as de-
scribed previously [24]. Briefly, sera were treated with receptor
destroying enzyme (RDE), serially diluted (2 fold) in V-bottom 96-
well plates and then mixed with a standard amount of virus. Plates
were incubated for 30 min at room temperature, and 1% chicken
red blood cells were added to each well. The hemagglutination
inhibition endpoint was the highest serum dilution in which
agglutination was not observed.
Microneutralization assay
Serum neutralizing antibody titers were determined by a
multiwell plate cell culture assay as previously described [17].
Briefly, MDCK cells were seeded at 1610
4 cells/well in 96-well
culture plates and cultured at 37uCi n5 %C O 2 to form a
monolayer. Serial two fold dilutions of RDE treated serum
samples were mixed separately with 100 TCID50 of A/Indonesia/
CDC669/06 (H5N1) and incubated at room temperature for 1 h.
The mixture was added to monolayer of MDCK cells in triplicate
wells. The plates were incubated for 2 days at 37uC in DMEM
supplemented with 1 mg/ml of TPCK-treated trypsin. The
neutralizing titer was assessed as the highest serum dilution in
which no cytopathic effect was observed by light microscope.
Results
Characterization of mAbs
Seven hybridomas secreted antibodies that bound to H5 HA1
expressed in recombinant baculovirus-infected insect cells and to
H5N1 virus-infected MDCK cells by IFA (data not shown) were
isolated. On the basis for lack of cross-reactivity with H1N1 and
H3N2 virus-infected cells, we selected one hybridoma, 5F8 for
further characterization. This hybridoma was biologically cloned
twice by limiting dilution before production of mAb-containing cell
culture fluid for the present study. mAb 5F8 yielded cytoplasmic
immuofluorescence in MDCK cells infected with A/Indonesia/
CDC594/06 (H5N1) virus (Fig. 1A) and Sf-9 cells infected with H5-
HA1 recombinant baculovirus (Fig. 1C). In contrast, no fluores-
cence signal was observed in MDCK cells infected with an H7N1
virus (Fig. 1B) and viruses from 4 other subtypes listed in Table 1
(results not shown). Neutralization assays indicated that 5F8 does
not affect the infectivity of A/Indonesia/CDC669/06 (H5N1) (data
not shown). The sensitivity and specificity profiles of mAb 5F8
established by IFAindicated that this mAbmet the requirements for
epitope mapping and further EB-ELISA development. The 5F8
mAb was identified as IgM class.
Epitope mapping of mAb 5F8
The 5F8 mAb recognized the HA1 domain of H5 by Western
blot assays (data not shown), suggesting that the epitope is either
linear or readily refolded through short-range interactions. This
property was exploited to map the HA epitope targeted by 5F8.
To this end, partially overlapping expressed HA fragments were
probed by Western blot analysis (Fig. 2A). mAb 5F8 reacted
exclusively with fragment ‘‘e’’ (amino acids 225–321 of mature
HA) (Fig. 2B). A panel of C-terminal nested deletions (SF1 through
SF8) generated to refine the epitope map revealed that 5F8 mAb
reacted with fragments SF4–SF8, indicating that the epitope
comprised amino acids 274 to 284 (Fig. 2A and 2C). Subsequent
analysis of a panel of expression constructs with single amino acid
changes analyzed by Western blot indicated that 5F8 bound to
mutants Y271A, G272A, N273A, M282A, G283A and A284G. In
contrast, 5F8 failed to bind mutants C274A, N275A, T276A,
K277A, C278A, Q279A, T280A, and P281A by Western blots
(Fig. 2D). These results suggested that amino acids 274–281
(CNTKCQTP) were required for mAb 5F8 binding.
Epitope analysis
Full length HA sequences from influenza A virus strains
(n=4143) were obtained from the Influenza Virus Database
maintained by the National Center for Biotechnology Informa-
tion. The available HA sequences from H5N1 viruses isolated
from humans (n=163) revealed that the CNTKCQTP epitope
recognized by 5F8 mAb is conserved in all these viruses whereas
the conservation rate is 96.9% among the additional 906 H5N1
viruses isolated from avian sources. Of the 162 H5 viruses with NA
subtype other than N1 (H5N2-N9), the 5F8 epitope is present in
54.3% of the viruses (Table 3). Thus, the conservation rate of the
5F8 epitope among all avian H5 viruses is 91.7%. This epitope
was absent among the HAs of subtype H2, H3, H4, H6-16 viruses
(n=2302). Although the epitope was present in 14 of the 610 H1
subtype viruses (approximately 2.3%), 13 of these viruses were
isolated before 1991 and the last one in 1999 (data not shown). On
the other hand, HA sequences of all H5N1 viruses used in this EB-
ELISA study were found to have the CNTKCQTP epitope.
Antisera to HA subtypes and H5N1 clades
A panel of antisera to influenza A viruses from various subtypes
was developed to determine the specificity of mAb 5F8 in an
epitope-blocking assay. Viruses from H5N1 clades or HA subtypes
that were not available in our laboratory were rescued by reverse
genetics as reassortants with the six internal genes (PB2, PB1, PA,
NP, M and NS) from A/Puerto Rico/8/34. Seventeen H5N1
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clades 0, 1, 2.1, 2.2, 2.3, 4, 7, and 8 were generated (Table 2). The
newly derived clade 1, 2.2 and 2.3 H5N1 reassortants included
strains recommended by WHO for vaccine development (Table 2)
[25]. Four additional subtypes, H2N9, H6N8, H8N4 and H12N5,
were also generated as reassortant viruses. These viruses were
subsequently used to immunize chickens and produce antisera to
evaluate the EB-ELISA. The initial characterization of the
immune response of chickens to the homologous viruses was
characterized by HI tests (Table 4).
Development of an epitope-blocking (EB) ELISA assay
Serum antibodies to the H5 HA can be detected by virtue of
their ability to block the binding of a mAb to the target epitope in
an ELISA assay. To develop this assay, we relied on serum panels
from normal and influenza-immunized chickens. First, a panel of
126 normal chicken serum samples lacking antibodies to influenza
virus was used to determine the baseline of non-specific reduction
in 5F8 binding to H5 antigen in the EB-ELISA. Mean reduction of
EB-ELISA readings (i.e. blocking) was 8.5% for this serum panel,
with a standard deviation (SD) of 9.3. Specific blocking activities
can be determined with 95% confidence if a ‘‘cut-off value’’ of
$30% is set for chicken serum samples. The latter was obtained
by adding 2 SD to the mean 8.5% blocking (8.5+18.6=27.1%).
The sensitivity and specificity of the mAb 5F8-based EB-ELISA
was investigated using a panel of antisera from experimentally
immunized chickens. Chicken sera collected 10 days after the 2
nd
immunization were first diluted to obtain HI titer of 16 to the
homologous virus to normalize antibody concentrations prior to
use in EB-ELISA. The EB-ELISA endpoint of the HI-normalized
sera was then determined by further analysis of log2 serial
dilutions. Sera from chickens immunized with H5N1 reassortant
influenza viruses (Table 2) yielded mAb 5F8 blocking values above
the 30% cutoff in EB-ELISA (Fig. 3). Many samples showed
.65% inhibition at dilutions well below detection by HI titer (,4)
indicating that the EB-ELISA detected low levels of antibody to
H5 (Fig. 3). Moreover, sera from chickens immunized with H1–
H4, H6–H10 and H12 showed maximum blocking of ,10%, well
Figure 1. Monoclonal antibody characterization by immunofluorescence assay. Indirect immunofluorescence assay with cells infected with
H5N1 virus or recombinant baculovirus expressing H5 HA. Infected cells were fixed and stained with mAb 5F8 and FITC-conjugated goat anti-mouse
immunoglobulin. MDCK cells infected with A/Indonesia/CDC594/06 fixed at 12 h post-infection were stained with 5F8 (A); Sf9 insect cells infected
with recombinant baculovirus expressing H5 HA1 were stained with 5F8 (B); mAb 5F8 did not bind to MDCK cells infected with A/common iora/
Indonesia/F89/11/95 (H7N1) (C); and also failed to bind to Sf-9 cells infected with wt baculovirus (D).
doi:10.1371/journal.pone.0004566.g001
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specific antibodies (Fig. 3). These results indicate that the EB-
ELISA could positively identify serum samples containing
antibodies to H5 and most importantly, sera containing antibodies
to other HA subtypes tested negative for H5N1. Furthermore,
similar test results were observed with rH5 HA or whole
inactivated H5N1 virions as coating antigens for the EB-ELISA
(Fig. 3). Use of recombinant HA antigen provides an attractive safe
alternative to H5N1 viral antigen for antibody detection assays.
The relative sensitivity of EB-ELISA and HI assays was further
compared by endpoint dilution analysis. Chicken antisera (n=5)
collected 10 days after first immunization with 26 H5N1
Indonesian strains (Table 1) tested positive in EB-ELISA with
cut-off value of .30% and achieving a mean titer of 52. Sera
collected 10 days after the 2
nd immunization showed mean
endpoint dilution titer of .334.67 in the EB-ELISA. In contrast,
HI assays showed very low levels of antibody (HI titer of ,12) on
day 10 after the 1
st immunization, reaching higher levels on day 10
after 2
nd immunization (mean HI titer 85). Sera from chickens
immunized with HA subtypes other than H5N1 showed no
significant inhibition in EB-ELISA. H3N2 immune chicken sera
peaked with a mean HI titer of 6 in HI assay against H5N1
antigen on day 10 after the 2
nd immunization (Table 4).
Performance of EB-ELISA relative to microneutralization
assay
The sensitivity of EB-ELISA was also compared to the
microneutralization assays which are currently recommended for
serological diagnosis of human H5N1 infection. Serum samples
from chickens immunized with H5N1 were normalized to HI titer
of 16 to the homologous viruses prior to titer determination in the
EB-ELISA. H5N1 antisera to viruses from different clades tested
positive in EB-ELISA with cut-off value of .30% blocking at a
mean end point serum dilution of 44.8 (38.4–51.2). In contrast,
serum samples to virus subtypes other than H5N1 tested negative
in EB-ELISA (Fig. 4). The clade 2.1 and clade 2.2 H5N1 antisera
showed neutralizing antibody titer of 44.8 and 38.4 respectively.
H5N1 clade 0, 2.3 and 7 showed neutralizing antibody titers ,30
(Fig. 4). Interestingly, serum samples from other clades (clade 1,
clade 4 and clade 8) showed neutralizing antibody titers below 20
against H5N1 viruses from clade 2.1 (Fig. 4). In addition, H4N1
and H7N1 antisera yielded negligible neutralizing antibody titers
against H5N1 (Fig. 4).
Human serum samples
To determine whether the 5F8 epitope was consistently
recognized by antibodies elicited by natural H5N1 infection in
humans, convalescent serum samples from individuals with a
laboratory-confirmed H5N1 infection were evaluated in the EB-
ELISA. Ten serum samples from patients who had recovered from
H5N1 influenza infection tested positive in EB-ELISA performed
with mAb 5F8 with mean percent blocking of 73.16 (63.81–
83.46%, Table 5). However, these samples showed a low mean HI
titer of ,16 (8–32 HI titer). Eight of these ten human serum
samples showed HI titer of 8–16 and only two samples reached the
HI titer of 32 against H5N1 virus from clade 2.1 (Table 5). Sera
from patients recovered from seasonal influenza A virus infection
yielded negative EB-ELISA results; a maximum blocking of ,13%
was noted. However, some of the convalescent influenza A human
serum samples (4 out of 15 samples) showed HI titer of 8 against
H5N1 virus, indicating some degree of cross-reactivity. Normal
Figure 2. Mapping the mAb 5F8 epitope. (A) Fragments of the H5
HA coding region (termed ‘‘a’’ through ‘‘e’’ and SF1 to SF8; their
boundaries indicated by N terminal and C terminal codon positions in
HA) were expressed as histidine N-terminal-tagged fusion proteins.
mAb 5F8 binding to fragments ‘‘a’’ through ‘‘e’’ (B) and sub-fragments
SF1 to SF8 (from fragments ‘‘d’’ and ‘‘e’’) in Western blot (C). +: rH5HA1
protein used as control. Western blot analysis of histidine-tagged HA
sub-fragments (SF3 and SF4) with single amino acid substitutions
revealed that binding by mAb 5F8 depends on the presence of specific
amino acids spanning positions 274–281 (D).
doi:10.1371/journal.pone.0004566.g002
Table 3. Frequency of Monoclonal antibody 5F8 epitope
among HA subtypes.
HA Subtype Virus Host
5F8 epitope/
total number
of sequences
Conservation
rate (%)
H5N1 Human 163/163 100%
H5N1 Avian 878/906 96.9%
H5Nx (x=2, 3, 5–9) Avian 88/162 54.3%
H1 Avian, human 14/610 2.3%
H3, H4, H6, H7, H8,
H9, H10, H11, H12,
H13, H14, H15 and H16
Avian, human 0/2302 0%
doi:10.1371/journal.pone.0004566.t003
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These data further establish the reliability of EB-ELISA to
positively detect H5 antibodies in serum samples from infected
hosts without significant false-negative test results due to antibodies
elicited by seasonal influenza viruses.
Discussion
Active serological surveillance for HPAI H5N1 viruses is crucial
for early detection and control of this emerging human pathogen.
The conventional subtype-specific methods for serological surveil-
lance are HI, microneutralization assay and ELISA, but these tests
have significant limitations. The need for a sensitive and specific
serological assay for detection of human antibodies to H5N1 has
not been met [26]. Blocking-ELISA offers considerable advantages
for detection of viral antibodies. A blocking-ELISA based on a
mAb against influenza A nucleoprotein (NP) has been reported as
quicker and more sensitive than HI for detection of influenza A
virus infection [27]. In addition, EB-ELISA has been used for
sensitive and specific detection of antibodies to many other viral
pathogens [28–32]. In particular, development of a blocking-
ELISA for specific detection of antibodies to low pathogenic avian
influenza (LPAI) subtype H5N2 viruses was reported recently [33].
The 5F8 mAb selected for this study was found to recognize an
epitope including the sequence CNTKCQTP in the HA1 region
of the H5 HA. Analysis of this epitope in 4143 influenza A viruses
HA sequences from the known subtypes (H1 through H16)
revealed that this epitope is highly conserved in H5N1 viruses. The
conservation rate of the epitope was absolute (100%) among
H5N1 viruses isolated from humans, indicating that this 5F8 mAb-
Table 4. EB-ELISA with immunized chicken sera.
Chicken serum against (n=5/group) Day 10 after 1
st Immunization Day 10 after 2
nd Immunization
HI titer
# EB-ELISA* HI titer
# EB-ELISA*
26 Indonesian H5N1 strains from clade 2.1 (n=5/group) 11.7960.98
a 52.6763.10 84.67610.40 334.67625.40
ck/Sg/02 (H3N2) 3.560.50 0 6.061.55 0
ck/Sg/92 (H4N1) 0 0 0 0
ck/Sg/94 (H7N1) 0 0 0 0
#Against H5N1 strain A/Indonesia/CDC669/06.
*Highest serum dilution blocking .30%.
aGeometric mean6Standard Error (SE).
doi:10.1371/journal.pone.0004566.t004
Figure 3. Sensitivity and specificity of the EB-ELISA. Performance of the EB-ELISA with sera from chickens immunized with different clades of
H5N1 and other HA subtypes. Chicken sera collected 10 days after second immunization were adjusted to HI titer of 16 and subsequently diluted 5-
fold for analysis in EB-ELISA. Antisera to H5N1 clade 0, 1, 2.1, 2.2, 2.3, 4, 7 and 8 and to other subtypes such as H2N9, H3N2, H4N1, H6N8, H7N1, H8N4,
H9N2, H10N5 and H12N5 were analysed. Inhibition above the cut-off value of .30% blocking was considered as positive; i.e. antibodies to H5N1
were present. The results were expressed as the arithmetic mean of percent blocking values (n=5/group, whiskers above bars represent the standard
error of the mean). NS: Normal preimmune chicken serum.
doi:10.1371/journal.pone.0004566.g003
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H5N1 antibodies in human sera. The epitope is also highly
conserved in H5N1 viruses isolated from avian sources (96.9%).
The 5F8 epitope was also found in 54% of low pathogenic avian
H5 viruses (H5N2-N9), therefore, the 5F8 mAb-based blocking-
ELISA could not distinguish between HPAI H5N1 viruses and low
pathogenic H5 subtypes in animals. However, low pathogenic H5
subtype viruses in poultry are also a serious concern due to their
propensity to mutate and acquire high virulence. Therefore,
detection of H5N1 antibodies using this EB-ELISA can also be
especially useful in serological surveillance for H5 virus infection in
poultry and wild birds. Of the 2812 non-H5 subtype viruses
analyzed, only 14 H1 subtype viruses (2.3%) were found to contain
the 5F8 epitope (CNTKCQTP). Interestingly, these H1 subtype
viruses were isolated between 1990 and 1999, suggesting that this
epitope has become extinct in this subtype. We postulate that the
H1N1-elicited 5F8 cross-reactive antibodies that could interfere in
the H5 EB-ELISA can be considered relatively low.
The H5 HA genes of HPAI influenza viruses are classified into
distinct phylogenic clades and subclades, many of which were
targeted for development of H5N1 vaccine candidates [34]. Our
data showed that mAb 5F8-based EB-ELISA was able to detect
H5N1 antibodies in sera of chickens immunized with H5N1 clades
0, 1, 2.1, 2.2, 2.3, 4, 7 and 8, suggesting that the 5F8 epitope is
highly antigenic regardless of the contextual sequence difference
between clades. Responses to clade 1, 2.1, 2.2 and 2.3 HA are
particularly relevant because these viruses caused the most human
infections in Asia, Africa and Europe [25].
Our results suggest that the blocking-ELISA using 5F8 mAb
was more effective for detection of H5N1 antibodies than HI and
microneutralization assay in terms of sensitivity. Previous studies
indicated that the microneutralization assay was the most sensitive
method for detection of H5N1 antibodies [26]. However, other
reports noted that cross-reacting antibodies from infection with
other subtypes limited the specificity of the assay [35–37].
Forty-five human serum specimens with known H5N1 exposure
history were used to evaluate the performance characteristics of
the EB-ELISA. In agreement with chicken antisera results, the 5F8
blocking-ELISA detected H5N1 antibodies in convalescent human
sera and yielded no false-positive test with convalescent sera from
seasonal influenza virus injections. Further studies are planned to
determine whether the EB-ELISA will be useful to measure
humoral antibody responses elicited by inactivated H5N1 pre-
pandemic vaccines.
In summary, the EB-ELISA developed in this study has
significant advantages relative to HI and microneutralization
assay for the detection H5N1 antibodies. Consistent blocking of
the 5F8 epitope by antibodies sera from chickens immunized with
Figure 4. Comparison of EB-ELISA to microneutralization
assay. The H5N1 antibody detection sensitivity and specificity of the
EB-ELISA and microneutralization assays were compared using immune
chicken sera collected 10 days after second immunization (adjusted to
HI titer of 16) to determine the endpoint of inhibition. Chicken antisera
to clade 0 (A/HK/156/97), 1 (A/Vietnam/1203/04), 2.1 (A/Indonesia/
CDC1031/07), 2.2 (A/turkey/Turkey1/05), 2.3 (A/Anhui/1/05), 4 (A/
Guiyang/337/06), 7 (A/Shanxi/2/06) and 8 (A/chicken/Henan/12/04) as
well as H4N1, H7N1 and H9N2 were used. The EB-ELISA titer was
determined as described in the Methods section. The neutralization
assays were performed using H5N1 virus A/Indonesia/CDC669/06. The
results were expressed as the geometric mean titers (n=5/group,
whiskers above bars represent the standard error of the mean).
doi:10.1371/journal.pone.0004566.g004
Table 5. Analysis of human serum samples in EB-ELISA.
Clinical human serum
samples
HI titer against
H5N1*
Inhibition in
EB-ELISA* (%)
H5N1 recovered serum
Indonesia/16_ 16 79.47
Indonesia/292 32 83.46
Indonesia/330 16 76.17
Indonesia/530 16 74.23
Indonesia/554 32 78.37
Indonesia/563 16 78.37
Indonesia/645 16 63.81
Indonesia/650 8 67.14
Indonesia/721 16 65.87
Indonesia/828 16 73.38
Non-H5 influenza A serum
9398 8 12.84
9286 ,8 12.56
9216 ,8 11.28
9159 ,8 6.72
9151 8 11.63
9140 ,8 12.83
9115 8 9.48
9129 ,8 7.19
9873 ,8 8.86
9106 8 9.43
9708 ,8 12.16
9824 ,8 8.38
9872 8 11.81
9624 ,8 12.78
9792 ,8 11.29
Normal human serum
n=20 0.060.0
a 9.93%63.099
a
*Titer expressed relative to neat serum.
aMean value6S.D of twenty serum samples (n=20).
doi:10.1371/journal.pone.0004566.t005
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highlights the high antigenicity of this epitope. The conservation of
this epitope (CNTKCQTP, aa 274–281; equivalent to 277 to 284
in H3 numbering) [38] in influenza H5 HA and its near complete
absence in other subtypes indicates that mAb 5F8 meets the
critical requirement for diagnosing H5 influenza virus infections
using the epitope-blocking assay format. Taken together, these
data suggest that this EB-ELISA is an attractive option for
detection of antibodies to H5N1 viruses in human and animal sera
with potential application for sero-diagnosis and surveillance.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0004566.s001 (0.03 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0004566.s002 (0.03 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0004566.s003 (0.03 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0004566.s004 (0.04 MB
DOC)
Acknowledgments
The authors are grateful for the financial support received from Temasek
Life Science Laboratory, Singapore. Special thanks to the Ministry of
Health (MOH), Indonesia, for contributing H5N1-infected specimens and
viruses as well as the Singapore General Hospital (SGH), Singapore for
providing us with the clinical samples used in this work. The findings and
conclusions in this report are those of the authors and do not necessarily
represent the views of the Centers for Disease Control and Prevention or
the Agency for Toxic Substances and Disease Registry. The authors do not
have any commercial or other association that might pose a conflict of
interest.
Author Contributions
Conceived and designed the experiments: MP JK. Performed the
experiments: MP NP SV. Analyzed the data: MP HTH NP ROD JK.
Contributed reagents/materials/analysis tools: HTH MS FH KPC LMC
YM ROD. Wrote the paper: MP HTH NP.
References
1. WHO. H5N1 Avian influenza: Timeline of major events.2008. http://www.
who.int/csr/disease/avian_influenza/timeline2008_01_02.pdf. Accessed 03
January, 2008.
2. WHO. H5N1 Avian influenza: Timeline of major events.2007. http://www.
whoint/csr/disease/avian_influenza/timeline2007_06_21pdf. Accessed 18 Sep-
tember, 2007.
3. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/
(H5N1) Reported to WHO 10 September 2008. http://www.who.int/csr/
disease/avian_influenza/country/cases_table_2008_09_10/en/index.html. Ac-
cessed 15 September, 2008.
4. WHO. Avian influenza-situation in Indonesia-update 16. http://www.who.int/
csr/don/2008_06_19/en/index.html. Accessed 19 June 2008.
5. Mounier-Jack S, Coker RJ (2006) How prepared is Europe for pandemic
influenza? Analysis of national plans. Lancet 367: 1405–1411.
6. Sedyaningsih ER, Isfandari S, Setiawaty V, Rifati L, Harun S, et al. (2007)
Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June
2006. J Infect Dis 196: 522–527.
7. Julkunen I, Phyala R, Hovi T (1985) Enzyme immunoassay, complement
fixation and hemagglutination inhibition tests in the diagnosis of influenza A and
B virus infections: purified hemagglutinin in subtype specific diagnosis. J Virol
Methods 10: 75–84.
8. Massicot J, Murphy BR (1977) Comparison of the hemagglutination-inhibiting
and neutralizing antibody responses of volunteers given 400 chick cell–
agglutinating units of influenza A/New Jersey/76 split-virus vaccine. J Infect
Dis 136: S472–474.
9. WHO. Recommendations and laboratory procedures for detection of avian
influenza A (H5N1) virus in specimens from suspected human cases; 2007. http://
www.who.int/csr/disease/avian_influenza/guide-ines/RecAllabtestsAug07.pdf.
Accessed May 1st, 2008.
10. Petric M, Comanor L, Petti CA (2006) Role of the laboratory in diagnosis of
influenza during seasonal epidemics and potential pandemics. J Infect Dis 194:
S98–110.
11. Stlzer-Braid S, Wong B, Robertson P, Lynch GW, Laurie K, et al. (2008) A
commercial ELISA detects high levels of human H5 antibody but cross-reacts
with influenza A antibodies. J Clin Virol 43: 241–243.
12. Hall RA, Broom AK, Hartnett AC, Howard MJ, Mackenzie JS (1995)
Immunodominant epitopes on the NS1 protein of MVE and KUN viruses serve
as targets for a blocking ELISA to detect virus-specific antibodies in sentinel
animal serum. J Virol Methods 51: 201–210.
13. Blitvich BJ, Marlenee NL, Hall RA, Bunning ML, Beaty BJ (2003) Epitope-
blocking enzyme linked immunosorbent assays for the detection of serum
antibodies to west nile virus in multiple avian species. J Clin Microbiol 41:
1041–1047.
14. WHO (2005) Evolution of H5N1 Avian Influenza Viruses in Asia. Emerg Infect
Dis 11: 1515–1521.
15. He Q, Velumani S, Du Q, Lim CW, Ng FK, et al. (2007) Detection of H5 avian
influenza viruses by antigen-capture enzyme-linked immunosorbent assay using
H5-specific monoclonal antibody. Clin Vaccine Immunol 14: 617–623.
16. Anonymous (1995) Laboratory biosafety manual. World Health Organization.
Ann Ist Super Sanita 31: 1–121.
17. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, et al. (2008)
Protective immunity against Influenza H5N1 virus challenge in mice by
intranasal co-administration of Baculovirus surface-displayed HA and recombi-
nant CTB as an adjuvant. Virology 380: 412–420.
18. Centers for Disease Control and Prevention (U.S.), and National Institutes of
Health (U.S.) (1999) Biosafety in microbiological and biomedical laboratories,
4th ed. Washington [Bethesda, Md.].Washington, D.C.: U.S. Dept. of Health
and Human Services Public Health Service Centers for Disease Control and
Prevention; National Institutes of Health; For sale by the Supt. of Docs. U.S.
G.P.O.
19. WHO (2004) Laboratory biosafety manual, 3rd ed. Geneva: World Health
Organization.
20. Yokoyama WM (2004) Production of monoclonal antibody. Current Protocols in
Immunology. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM,
Strober W, eds. Newcastle, United Kingdom: John Wiley & Sons. Inc. pp
2.5.1–2.5.17.
21. New N, He Q, Damrongwatanapokin S, Du Q, Manopo I, et al. (2006)
Expression of hemagglutinin protein from the avian influenza virus H5N1 in a
baculovirus/insect cell system significantly enhanced by suspension culture.
BMC Microbiol 6: 16.
22. Velumani S, Du Q, Fenner BJ, Prabakaran M, Wee LC, et al. (2008)
Development of an antigen-capture ELISA for detection of H7 subtype avian
influenza from experimentally infected chickens. J Virol Methods 147: 219–225.
23. Gallgher S, Winston SE, Fuller SA, Hurrell JGR (2004) Immunoblotting and
immunodetection. Current Protocols in Molecular Biology Ausubel FM, Brent R,
Kingston RE, Moore DD, et al., eds. Newcastle, United Kingdom: John
Wiley&Sons. Inc. pp 10.8.1–10.8.24.
24. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E (1991) Efficacy of
nucleoprotein and hemagglutinin antigens expressed in fowlpox virus as vaccine
for influenza in chickens. Vaccine 9: 303–308.
25. WHO (2007) Antigenic and genetic characteristics of H5N1 viruses and
candidate H5N1 vaccine viruses developed for potential use as pre-
pandemic vaccines. http://www.who.int/csr/disease/avian_influenza/guidelines/
recommendationvaccine.pdf. Accessed August 22th, 2008.
26. Rowe T, Abernathy RA, Hu-Primmer J, Thomson WW, Lu X, et al. (1999)
Detection of antibody to avian influenza A (H5N1) virus in human serum by
using a combination of serologic assays. J Clin Microbiol 37: 937–941.
27. de Boer F, Back W, Osterhaus ADME (1990) An ELISA for detection of
antibodies against influenza A nucleoprotein in humans and various animal
species. Arch Virol 115: 47–61.
28. Singh BK, Ahuja S, Gulati BR (2004) Developmental of a monoclonal antibody-
based blocking ELISA for detection of Equine Herpusvirus 1 antibodies. Vet Res
Comm 28: 437–446.
29. Gut-Winiarska M, Jacobs L, Kerstens H, Bienkowaska-Szewczyk K (2000) A
highly specific and sensitive sandwich blocking ELISA based on baculovirus
expressed pseudorabis virus glycoprotein B. J Virol Methods 88: 63–71.
30. Kuck D, Kern A, Kleinschmidt JA (2007) Developmental of AAV serotype-
specific ELISAs using novel monoclonal antibodies. J Virol Methods 140: 17–24.
31. Ameri-Mahabadi M, Zhou E, Hsu WH (2005) Comparison of two swine
Mycoplasma hyopneumoniae enzyme-linked immunosorbent assays for detec-
Detection of Antibody to H5N1
PLoS ONE | www.plosone.org 9 February 2009 | Volume 4 | Issue 2 | e4566tion of antibodies from vaccinated pigs and field serum samples. J Vet Diagn
Invest 17: 61–64.
32. Fevereiro M, Barros S, Fagulha T (1999) Development of a monoclonal
antibody blocking-ELISA for detection o antibodies against Maedi-Visna virus.
J Virol Methods 81: 101–108.
33. Chen YC, Chen CH, Wang CH (2008) H5 antibody detection by blocking
enzyme-linked immunosorbent assay using a monoclonal antibody. Avian Dis
52: 124–129.
34. The Writing Committee of the World Health Organization (WHO) Consulta-
tion on Clinical aspects of human infection with Avian Influenza A (H5N1) virus
(2008) Update on Avian Influenza A (H5N1) virus infection in Humans.
N Engl J Med 358: 261–273.
35. Profeta ML, Palladino G (1996) Serological evidence of human infections with
avian influenza viruses. Arch Virol 90: 355–360.
36. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope
conserved between the hemagglutinins of influenza A virus H1 and H2 strains.
J Virol 67: 2552–2558.
37. Govorkova EA, Smirnov YA (1997) Cross-protection of mice immunized with
different influenza A (H2) strains and challenged with viruses of the same HA
subtype. Acta Virol 41: 251–257.
38. Ha Y, Stevens DJ, Skehel JJ, Wiley DC (2002) H5 avian and H9 swine influenza
virus haemagglutinin structures: possible origin of influenza subtypes. EMBO J
21: 865–875.
Detection of Antibody to H5N1
PLoS ONE | www.plosone.org 10 February 2009 | Volume 4 | Issue 2 | e4566